{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'Title: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled', 'Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of', 'Elamipretide in Subjects with Primary Mitochondrial Myopathy Followed by an', 'Open-Label Treatment Extension', 'NCT: NCT03323749', 'Final Approval Date: 15 June 2018', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '1', '00900-4.00']['SPIMM-301 Version 4.0', '15 June 2018', 'CLINICAL TRIAL PROTOCOL', 'A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-', 'Controlled Trial to Evaluate the Efficacy and Safety of Daily', 'Subcutaneous Injections of Elamipretide in Subjects with', 'Primary Mitochondrial Myopathy Followed by an Open-Label', 'Treatment Extension', 'Trial Phase:', 'Phase 3', 'Trial Number:', 'SPIMM-301', 'Document Version:', 'Version 4.0', 'Final Approval Date:', '15 June 2018', 'IND Number:', '123,553', 'EudraCT Number:', '2017-002447-15', 'Sponsor:', 'Stealth Bio Therapeutics Inc.', '275 Grove Street, Suite 3-107', 'Newton, MA 02466', 'United States of America (USA)', 'Sponsor Chief Clinical', 'Jim Carr, Pharm.D.', 'Development Officer:', 'Chief Clinical Development Officer', '275 Grove Street 3-107, Newton, MA 02466, USA', 'Jim.Carr@,StealthBT.com', '+1 617-762-2503', 'Sponsor Medical Monitor:', 'Sandrin Bergheanu, M.D., Ph.D', 'Medical Monitor', '275 Grove Street 3-107, Newton, MA 02466, USA', 'Sandrin.Bergheanu@StealthBT.com', '+1 617-762-2595', '+31 (0) 641 476 460', 'Confidentiality Statement', 'The information contained in this document is confidential and is the property of Stealth', 'Bio Therapeutics Inc. No part of it may be transmitted, reproduced, published, or used by', 'anyone without the written permission of Stealth Bio Therapeutics Inc.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '1', '00900-4.00']['SPIMM-301 Version 4.0', '15 June 2018', 'PROTOCOL APPROVAL', 'Protocol Title:', 'A Phase 3 Randomized, Double-Blind, Parallel-Group,', 'Placebo-Controlled Trial to Evaluate the Efficacy and', 'Safety of Daily Subcutaneous Injections of Elamipretide', 'in Subjects with Primary Mitochondrial Myopathy', 'Followed by an Open-Label Treatment Extension', 'Protocol Number:', 'SPIMM-301', 'Protocol Date:', '15 June 2018, Version 4.0', 'Jim Carr', '06/15/2018', 'Jim Carr, Pharm. D.', 'Date', 'Chief Clinical Development Officer', 'Stealth Bio Therapeutics Inc.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '2']\n\n###\n\n", "completion": "END"}